Investor Relations

Latest Financial Results

Q2 2021

Quarter Ended Jun 30, 2021

Company Overview

XORTX Therapeutics Inc. is a pharmaceutical company, developing drug based products for two clinically advanced products – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.

Stock Snapshot

XORTX Therapeutics Inc.

View Detailed Stock Information

IR Contacts

Company

XORTX Therapeutics Inc.
4000, 421 - 7th Avenue SW
Calgary, Alberta T2P 4K9
Canada
T: 403-455-7727
info@xortx.com

Investor Relations

Allen Davidoff
CEO
T: 403-455-7727
adavidoff@xortx.com

Nick Rigopulos
Director of Communications
T: 617-901-0785
nick@alpineequityadv.com

Transfer Agent

TSX Trust Company
Investor Services
100 Adelaide Street West
Suite 301
Toronto, ON M5H 4H1
Canada
T: 416-342-1091
tmxeinvestorservices@tmx.com